Oaktree Acquisition Corp. III Life Sciences extended its combination deadline to November 25, 2026, after holders of 11,331,102 public shares redeemed them for an aggregate $122,435,287, leaving an approximately $85.0 million trust balance and substantial doubt about going concern.
OACCU · Oaktree Acquisition Corp. III Life Sciences
Substantial doubt about the company's ability to continue as a going concern.
“Such potential liquidity shortfalls and mandatory liquidation condition raise substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed Nov 13, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Latest documents
Oaktree Acquisition Corp. III Life Sciences shareholders approved extending its deadline from October 25, 2026 to November 25, 2026, with monthly extensions to May 25, 2027. Holders of 11,331,102 public shares redeemed them for approximately $122,435,287.
Oaktree Acquisition Corp. III Life Sciences postponed its extraordinary general meeting from October 16, 2026 to October 23, 2026 to permit further solicitation and vote of proxies on extending the date to complete an initial business combination.
Oaktree Acquisition Corp. III Life Sciences postponed its shareholder General Meeting, originally set for October 16, 2026, to October 23, 2026 at 10:00 a.m. Eastern Time to permit further proxy solicitation for the initial business combination extension proposal.
Oaktree Acquisition Corp. III Life Sciences reported 13,326,977 Class A shares tendered by the October 14, 2026 redemption deadline; conversion of 4,798,758 Class B shares into Class A shares would leave 11,254,791 Class A and 1,000 Class B shares outstanding.
Technicals
trend & momentum for long-term holders illustrative — not investment adviceIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Shell Companies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OACCU
this stock
Oaktree Acquisition Corp. III Life Sciences
|
$142.06M | +0.4% | — | — | — |
|
VYLR
Vylor Inc.
|
$46.59B | — | — | — | 2.1% |
|
CLUS
Cluster Group Holdings Ltd Co
|
$8.00B | — | — | — | — |
|
DMII
Drugs Made In America Acquisition II Corp.
|
$651.65M | +3.3% | — | — | 0.2% |
|
EVAC
EQV Ventures Acquisition Corp. II
|
$606.10M | +3.4% | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 152.5%
- Net QoQ
- -275.7K sh
- Top holder
- Fort Baker Capital Manage…
- Filed
- Nov 13, 2026
- This year
- 11
Oaktree Acquisition Corp. III Life Sciences extended its combination deadline to November 25, 2026, after holders of 11,331,102 public shares redeemed them for an aggregate $122,435,287, leaving an approximately $85.0 million trust balance and substantial doubt about going concern.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OACCU | -2.3% | -1.8% | +7.2% | -0.5% | +0.4% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -4.9% | -0.7% | +6.7% | -0.3% | -10.3% |